GERON CORP Cash and Cash Equivalents
GERON CORP (GERN) had Cash and Cash Equivalents of $62.64 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-05
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $62.64M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $68.89M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $77.56M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $78.12M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $62.64M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $68.89M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $77.56M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $78.12M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $77.73M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $83.75M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $79.02M 10-K · filed 2026-03-02 |
| 2024-09-30 | $60.34M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $116.94M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $189.76M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $70.02M 10-K · filed 2025-02-27 |
| 2023-09-30 | $30.71M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $56.90M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $112.78M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $56.84M 10-K · filed 2024-02-28 |
| 2022-09-30 | $61.10M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $76.06M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $31.32M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $34.87M 10-K · filed 2023-03-16 |
| 2021-09-30 | $29.04M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $57.28M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $31.54M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $9.93M 10-K · filed 2022-03-10 |
| 2020-09-30 | $44.96M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $22.86M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $20.29M 10-Q · filed 2020-05-28 |
| 2019-12-31 | $13.64M 10-K · filed 2021-03-11 |
| 2019-09-30 | $20.75M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $17.71M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $6.80M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $10.57M 10-K · filed 2020-03-12 |
| 2018-09-30 | $12.73M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $19.13M 10-Q · filed 2018-07-31 |
| 2018-03-31 | $7.91M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $16.34M 10-K · filed 2019-03-07 |
| 2017-09-30 | $9.90M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $6.61M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $14.86M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $12.81M 10-K · filed 2018-03-16 |
| 2016-09-30 | $5.88M 10-Q · filed 2017-11-01 |
| 2016-06-30 | $8.20M 10-Q · filed 2017-08-09 |
| 2016-03-31 | $12.80M 10-Q · filed 2017-05-09 |
| 2015-12-31 | $21.25M 10-K · filed 2018-03-16 |
| 2015-09-30 | $16.82M 10-Q · filed 2016-11-03 |
| 2015-06-30 | $15.80M 10-Q · filed 2016-08-03 |
| 2015-03-31 | $10.18M 10-Q · filed 2016-05-05 |
| 2014-12-31 | $42.80M 10-K · filed 2018-03-16 |
| 2014-09-30 | $7.60M 10-Q · filed 2015-11-05 |
| 2014-06-30 | $9.52M 10-Q · filed 2015-08-05 |
| 2014-03-31 | $11.32M 10-Q · filed 2015-05-07 |
| 2013-12-31 | $12.99M 10-K · filed 2017-03-01 |
| 2013-09-30 | $9.59M 10-Q · filed 2014-11-05 |
| 2013-06-30 | $8.83M 10-Q · filed 2014-08-11 |
| 2013-03-31 | $15.51M 10-Q · filed 2014-05-01 |
| 2012-12-31 | $22.06M 10-K · filed 2016-03-10 |
| 2012-09-30 | $16.01M 10-Q · filed 2013-11-07 |
| 2012-06-30 | $14.12M 10-Q · filed 2013-08-08 |
| 2012-03-31 | $19.03M 10-Q · filed 2013-05-03 |
| 2011-12-31 | $16.11M 10-K · filed 2015-03-11 |
| 2011-09-30 | $33.98M 10-Q · filed 2012-11-02 |
| 2011-06-30 | $32.02M 10-Q · filed 2012-08-03 |
| 2011-03-31 | $35.41M 10-Q · filed 2012-05-07 |
| 2010-12-31 | $45.97M 10-K · filed 2014-03-17 |
| 2010-09-30 | $34.49M 10-Q · filed 2011-11-03 |
| 2010-06-30 | $37.31M 10-Q · filed 2011-11-03 |
| 2009-12-31 | $34.60M 10-K · filed 2013-03-15 |
| 2008-12-31 | $109.35M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |